Zobrazeno 1 - 10
of 155
pro vyhledávání: '"K B, McCredie"'
Publikováno v:
Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis. 4(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::85bcbc801ad156532cd34cbc1744b8c5
https://pubmed.ncbi.nlm.nih.gov/10805427
https://pubmed.ncbi.nlm.nih.gov/10805427
Autor:
H M, Kantarjian, M, Talpaz, S, O'Brien, R, Kurzrock, J, Gutterman, M J, Keating, K B, McCredie, E J, Freireich
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 3(12 Pt 2)
The purpose of this study was to review the progress in clinical and translational research in chronic myelogenous leukemia (CML) over the past 20 years at M.D. Anderson Cancer Center. The CML database updating the clinical and basic research investi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8bcb4859420217aa6910cfb7ef636b1b
https://pubmed.ncbi.nlm.nih.gov/10068280
https://pubmed.ncbi.nlm.nih.gov/10068280
Autor:
J Q, Guo, C F, Hirsch-Ginsberg, Y M, Xian, S A, Stass, R E, Champlin, S A, Giralt, K B, McCredie, M L, Campbell, R B, Arlinghaus
Publikováno v:
Hematologic pathology. 7(2)
The benign phase of chronic myelogenous leukemia (CML) typically is characterized by an overproduction of myeloid cells that eventually progresses to a more acute stage termed blast crisis. This latter stage can exhibit either myeloid or lymphoid bla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::740d3a326ed940d5861377f0aa30346b
https://pubmed.ncbi.nlm.nih.gov/8340287
https://pubmed.ncbi.nlm.nih.gov/8340287
Autor:
E J, Freireich, A, Cork, S A, Stass, K B, McCredie, M J, Keating, E H, Estey, H M, Kantarjian, J M, Trujillo
Publikováno v:
Leukemia. 6(6)
Bone marrow samples collected from acute myeloblastic leukemia (AML) patients in complete clinical and hematological remission were studied for the persistence of cytogenetic abnormalities. AML patients from the three favorable cytogenetic categories
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::716b591e77885cafc805e2f069e4f010
https://pubmed.ncbi.nlm.nih.gov/1602788
https://pubmed.ncbi.nlm.nih.gov/1602788
Autor:
E H, Estey, R, Kurzrock, H M, Kantarjian, S M, O'Brien, K B, McCredie, M, Beran, C, Koller, M J, Keating, C, Hirsch-Ginsberg, Y O, Huh
Publikováno v:
Blood. 79(4)
We administered one course of 2-chlorodeoxyadenosine (2CdA) at 4 mg/m2 daily for 7 days by continuous intravenous infusion to 46 patients with hairy cell leukemia. Complete remissions occurred in 36 patients (78%; 95% confidence limits, 63% to 89%),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f215aa93611d93989e4e18b557c4eff2
https://pubmed.ncbi.nlm.nih.gov/1346577
https://pubmed.ncbi.nlm.nih.gov/1346577
Publikováno v:
Leukemia. 4(6)
The in vitro cytotoxic properties of acetaldoifosphamide, a new chemically stable bis-acetate analogue of aldoifosphamide that requires enzymatic activation by cellular carboxylate esterases, has been compared with that of 4-hydroperoxycyclophosphami
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2396a5c695555ee2bd4977a0b3636508
https://pubmed.ncbi.nlm.nih.gov/2359343
https://pubmed.ncbi.nlm.nih.gov/2359343
Publikováno v:
Cancer. 65(5)
One hundred three relapsed leukemia patients were treated with high-dose cytosine arabinoside (Ara-C); 3 g/m2 intravenously over 2 hours every 6 to 12 hours for a total of nine to 12 doses or 3 g/m2 intravenously over 2 hours for two doses 12 hours a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3c9c6b92e905ff17a7b356edd0b40aff
https://pubmed.ncbi.nlm.nih.gov/2302659
https://pubmed.ncbi.nlm.nih.gov/2302659
Publikováno v:
Leukemia. 4(2)
We evaluated relationships between ara-CTP pharmacokinetics in myeloblasts, response, and karyotype in 147 patients with newly diagnosed AML treated on three protocols each initiated by a 3 g/m2 ara-C dose given over 2 h. Area under the curve of ara-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::13057e83f4c6d417a6123ba4de0ee2b6
https://pubmed.ncbi.nlm.nih.gov/2304361
https://pubmed.ncbi.nlm.nih.gov/2304361
Publikováno v:
Haematology and blood transfusion. 33
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8ccddf7f976b5138f7f0b0a63aab22c7
https://pubmed.ncbi.nlm.nih.gov/2182449
https://pubmed.ncbi.nlm.nih.gov/2182449
Autor:
H M, Kantarjian, R L, Walters, M J, Keating, E H, Estey, S, O'Brien, J, Schachner, K B, McCredie, E J, Freireich
Publikováno v:
Cancer. 65(1)
Twenty-five adult patients with refractory acute lymphocytic leukemia received salvage therapy with mitoxantrone 5 mg/m2 intravenously over 1 hour daily for 5 days and cytosine arabinoside 3 g/m2 intravenously over 2 hours every 12 hours for six dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7a171788d971e4c07216c48cc0de32ce
https://pubmed.ncbi.nlm.nih.gov/2293869
https://pubmed.ncbi.nlm.nih.gov/2293869